Czech Mary M, Nayak Ashwin K, Subramanian Kavitha, Suarez Jose F, Ferguson Jessica, Jacobson Karen Blake, Montgomery Susan P, Chang Michael, Bae Gordon H, Raghavan Shyam S, Wang Hannah, Miranti Eugenia, Budvytiene Indre, Shoor Stanford Mervyn, Banaei Niaz, Rieger Kerri, Deresinski Stan, Holubar Marisa, Blackburn Brian G
Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA.
Department of Internal Medicine, Stanford University School of Medicine, Stanford, California, USA.
Open Forum Infect Dis. 2021 Feb 5;8(2):ofaa642. doi: 10.1093/ofid/ofaa642. eCollection 2021 Feb.
Reactivation of Chagas disease has been described in immunosuppressed patients, but there is a paucity of literature describing reactivation in patients on immunosuppressive therapies for the treatment of autoimmune rheumatic diseases. We describe a case of Chagas disease reactivation in a woman taking azathioprine and prednisone for limited cutaneous systemic sclerosis (lcSSc). Reactivation manifested as indurated and erythematous cutaneous nodules. Sequencing of a skin biopsy specimen confirmed the diagnosis of Chagas disease. She was treated with benznidazole with clinical improvement in the cutaneous lesions. However, her clinical course was complicated and included disseminated CMV disease and subsequent septic shock due to bacteremia. Our case and review of the literature highlight that screening for Chagas disease should be strongly considered for patients who will undergo immunosuppression for treatment of autoimmune disease if epidemiologically indicated.
恰加斯病(南美锥虫病)再激活在免疫抑制患者中已有报道,但描述接受免疫抑制疗法治疗自身免疫性风湿性疾病的患者发生再激活的文献较少。我们描述了1例因局限性皮肤型系统性硬化症(lcSSc)服用硫唑嘌呤和泼尼松的女性发生恰加斯病再激活的病例。再激活表现为皮肤硬结和红斑性结节。皮肤活检标本测序确诊为恰加斯病。她接受了苯硝唑治疗,皮肤病变有临床改善。然而,她的临床病程复杂,包括播散性巨细胞病毒病以及随后因菌血症导致的感染性休克。我们的病例及文献回顾强调,如果有流行病学指征,对于将接受免疫抑制治疗自身免疫性疾病的患者,应强烈考虑筛查恰加斯病。